Sugi Predict

Sugi Predict / Compounds / SCHEMBL1352508

SCHEMBL1352508

SCHEMBL1352508

Cc1ccc(N)c(CN)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ THRB P10828 1/20 0.54
▸ SLC6A2 P23975 1/20 0.49
▸ SLC6A4 P31645 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49
▸ TAAR1 Q96RJ0 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.46
▸ HSD17B10 Q99714 1/20 0.43
▸ CA1 P00915 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPT P10636 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27848958 0.98 TDP1 (0.52) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL12463289 0.83 ALOX15 (0.56) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL2014732 0.82 TAAR1 (0.67) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL31472985 0.81 ALOX15 (0.54) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL3682215 0.81 TDP1 (0.54) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL1261761 0.81 ALOX15 (0.54) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL22859097 0.80 TAAR1 (0.52) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL356244 0.79 ALOX15 (0.52) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL1352506 0.79 TDP1 (0.52) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL9508003 0.79 TDP1 (0.52) TDP1ALOX15CYP3A4SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105992756-B The method of hydroaromatic compound 巴斯夫欧洲公司 2018-09-21 — — CN claimed
CN-105992756-A Method for hydrogenating aromatic compounds 巴斯夫欧洲公司 2016-10-05 — — CN claimed
CN-101291990-B Thermosetting resin composition and use thereof NIPPON KAYAKU KK 2012-05-30 — — CN claimed
CN-102046279-A Continuous process and reactor for hydrogenating organic compounds BASF SE 2011-05-04 — — CN claimed
CN-101291990-A Thermosetting resin composition and use thereof NIPPON KAYAKU KK (JP) 2008-10-22 — — CN claimed
CN-1211743-A Multi-domain STN LCD comprising fluorinated polyimide alignment layers MERCK PATENT GMBH (DE) 1999-03-24 — — CN claimed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 — — US disclosed
EP-3077396-B1 SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF HOFFMANN LA ROCHE (CH) 2021-04-21 — — EP disclosed
CN-106902123-B Application of 5-hydro-1, 4-benzodiazepine compound in treating liver cancer 上海交通大学 2020-08-25 — — CN disclosed
CN-106883188-B 5-hydrogen-1, 4-benzodiazepine compound and synthesis method thereof 上海交通大学 2020-06-30 — — CN disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 — — US disclosed
CN-109640659-A Composition for inhibiting microorganisms 科莱恩国际有限公司 2019-04-16 — — CN disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 — — US disclosed
CN-1596288-A Flame-retardant resin composition POLYPLASTICS CO (JP) 2005-03-16 — — CN disclosed
CN-1519265-A Hydrogenation of methane diphenylamine homolog and epoxy resin cured therefrom �����Ʒ�뻯ѧ��˾ 2004-08-11 — — CN disclosed
CN-1441786-A Novel diamino pyrazole derivatives and dyes containing said compounds WELLA AG (DE) 2003-09-10 — — CN disclosed
CN-1293663-A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamix acids as matrix metal-protease AMERICAN CYANAMID CO (US) 2001-05-02 — — CN disclosed
CN-1211743-A Multi-domain STN LCD comprising fluorinated polyimide alignment layers MERCK PATENT GMBH (DE) 1999-03-24 — — CN disclosed
US-5234925-A Anticarcinogenic agent DANA-FARBER CANCER INSTITUTE, INC. (US) 1993-08-10 — — US disclosed
WO-1993004051-A1 2-AZA-2-DESAMINO ANALOGUES OF 5,8-DIDEAZAFOLIC ACID DANA-FARBER CANCER INSTITUTE, INC. (US) 1993-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR TDP1 4027/4885ALOX15 4571/4885CYP3A4 4458/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR TDP1 4027/4885ALOX15 4571/4885CYP3A4 4458/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR TDP1 4027/4885ALOX15 4571/4885CYP3A4 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.